var docs;if (!docs) docs =[]; docs["106"]={"10600":"<p><b>Title</b> HYDROcodone / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of HYDROcodone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Reduce the hydrocodone dose by 50% during concurrent use of ombitasvir, paritaprevir, and ritonavir; monitor closely for both analgesic effectiveness and for signs of toxicity or withdrawal. Following discontinuation of ombitasvir, paritaprevir, ritonavir, and dasabuvir, monitor clinical response to hydrocodone closely and adjust the hydrocodone dose as needed.</p> \n<p><b>Discussion</b> The hydrocodone AUC was increased by an average of 1.9-fold with concurrent ombitasvir, paritaprevir, ritonavir, and dasabuvir in a study of 15 subjects.<sup>1,2</sup> The specific mechanism for this interaction is uncertain, but inhibition of the CYP3A4- and/or CYP2D6-mediated metabolism of hydrocodone by ritonavir is one possible mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10601":"<p><b>Title</b> HYDROcodone / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of HYDROcodone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Reduce the hydrocodone dose by 50% during concurrent use of ombitasvir, paritaprevir, ritonavir, and dasabuvir; monitor closely for both analgesic effectiveness and for signs of toxicity or withdrawal. Following discontinuation of ombitasvir, paritaprevir, ritonavir, and dasabuvir, monitor clinical response to hydrocodone closely and adjust the hydrocodone dose as needed.</p> \n<p><b>Discussion</b> The hydrocodone AUC was increased by an average of 1.9-fold with concurrent ombitasvir, paritaprevir, ritonavir, and dasabuvir in a study of 15 subjects.<sup>1,2</sup> The specific mechanism for this interaction is uncertain, but inhibition of the CYP3A4- and/or CYP2D6-mediated metabolism of hydrocodone by ritonavir is one possible mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10602":"<p><b>Title</b> Pheniramine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Pheniramine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients to avoid the use of alcohol together with pheniramine.</p> \n<p><b>Discussion</b> The labeling for at least one pheniramine product states that patients should be cautioned against combining alcohol with other CNS depressants.<sup>1</sup> Pheniramine is a CNS depressant, and concurrent use with alcohol may result in excessive CNS depression.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Avil (pheniramine) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10603":"<p><b>Title</b> Esmolol / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: The significance of this interaction is higher with I.V. verapamil or diltiazem, where the combination is specifically contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Esmolol. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administration of IV verapamil or diltiazem together with esmolol is contraindicated if one agent is administered while the cardiovascular effects of the other are still present. The Canadian esmolol labeling specifies that use within 24 hours is contraindicated. With combined use of oral verapamil or diltiazem with esmolol, monitor for evidence of excessive bradycardia, heart block, or heart failure.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil, DilTIAZem, Verapamil</p>\n</div> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but the labeling for esmolol states that use with IV verapamil or diltiazem is contraindicated while the cardiovascular effects of esmolol are present.<sup>1,2</sup> The likely mechanism for this concern is additive or synergistic suppressant effects on heart rate, contractility, and blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brevibloc (esmolol) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2012.</p>\n<p>2. Brevibloc (esmolol) [product monograph]. Mississauga, Ontario, Canada: Baxter Healthcare Corporation; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10604":"<p><b>Title</b> Esmolol / Morphine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Morphine (Systemic) may increase the serum concentration of Esmolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response closely, and specifically monitor for evidence of excessive esmolol response.</p> \n<p><b>Discussion</b> According to the Canadian labeling for esmolol, concurrent use of morphine was associated with an average 46% increase in esmolol concentrations and no significant change in morphine concentrations.<sup>1</sup> Caution while initiating and titrating esmolol doses is warranted. The mechanism for this apparent interaction is unknown.<br><br>Two other studies have reported that administration of esmolol may lower morphine dose requirements. In one study of 60 subjects undergoing a cholecystectomy, the median morphine dose requirement was significantly lower in subjects randomized to esmolol than in those randomized to remifentanil plus ketamine (0 mg vs. 5 mg, respectively).<sup>2</sup> In another study the 3-day patient controlled analgesia consumption of morphine was significantly lower in the esmolol group than in the control group (37.3 mg vs. 54.7 mg, respectiveley) in a study of 92 subjects undergoing a hysterectomy.<sup>3</sup> The specific mechanism and clinical signifcance of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brevibloc (esmolol) [product monograph]. Mississauga, Ontario, Canada: Baxter Healthcare Corporation; May 2016.</p>\n<p>2. Lopez-Alvarez S, Mayo-Moldes M, Zaballos M, Iglesias BG, Blanco-Davila R. Esmolol versus ketamine-remifentanil combination for early postoperative analgesia after laparoscopic cholecystectomy: a randomized controlled trial. <i>Can J Anaesth</i>. 2012;59(5):442-448. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22383085\">[PubMed 22383085]</a></p>\n<p>3. Chia YY, Chan MH, Ko NH, Liu K. Role of beta-blockade in anaesthesia and postoperative pain management after hysterectomy. <i>Br J Anaesth</i>. 2004;93(6):799-805. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15377583\">[PubMed 15377583]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10605":"<p><b>Title</b> Succinylcholine / Esmolol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Esmolol may enhance the neuromuscular-blocking effect of Succinylcholine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of a prolonged duration of succinylcholine effects with concurrent use of esmolol.</p> \n<p><b>Discussion</b> Esmolol labeling states that concurrent use with succinylcholine was associated with a 5 to 8 minute prolongation of the neuromuscular blocking effects of succinylcholine.<sup>1,2</sup><br><br>The mechanism for this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brevibloc (esmolol) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2012.</p>\n<p>2. Brevibloc (esmolol) [product monograph]. Mississauga, Ontario, Canada: Baxter Healthcare Corporation; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10606":"<p><b>Title</b> Fingolimod / Esmolol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Esmolol may enhance the bradycardic effect of Fingolimod. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of this combination is not recommended. If the combination is necessary, monitor closely for evidence of excessive bradycardia, particularly following initiation of the combination (ie, at least overnight).</p> \n<p><b>Discussion</b> According to the Canadian labeling for esmolol, concurrent use of fingolimod is not recommended due to the potential for excessive bradycardia.<sup>1</sup> Caution while initiating esmolol doses is warranted for patients for whom the combination is considered necessary, and the Canadian labeling suggests a minimum of overnight monitoring. The mechanism for this apparent interaction is likely additive or synergistic bradycardic effects, as both esmolol and fingolimod are independently associated with bradycardia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brevibloc (esmolol) [product monograph]. Mississauga, Ontario, Canada: Baxter Healthcare Corporation; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10607":"<p><b>Title</b> Blood Pressure Lowering Agents / Nicergoline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nicergoline may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for hypotension if nicergoline is combined with blood pressure lowering agents.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Nicergoline prescribing information states that since nicergoline blocks alpha-1 receptors leading to systemic vasodilation, concomitant use with drugs that lower blood pressure may lead to an exaggerated hypotensive response.<sup>1,2</sup> Increased blood pressure monitoring is recommended if these agents are combined.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sermion (nicergoline) [BR prescribing information]. Sao Paulo, Brazil. Pfizer Ltda; November 2015.</p>\n<p>2. Sermion 10 mg (nicergoline) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199700555. Accessed December 17, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10608":"<p><b>Title</b> Nicergoline / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MMDL metabolite may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MDL metabolite may be decreased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased nicergoline toxicities, as well as reduced nicergoline efficacy, if combined with a strong CYP2D6 inhibitor.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Nicergoline is completely absorbed from the gastrointestinal system and immediately hydrolyzed to the MMDL metabolite. The MMDL metabolite is then metabolized by CYP2D6 to form the MDL metabolite.<sup>1</sup> In a pharmacokinetic study of healthy volunteers, extensive metabolizers of CYP2D6 had a mean MDL AUC that was significantly higher than the mean MMDL AUC (2,570 nmol.hr/L vs 148 nmol.hr/L).<sup>1</sup> In poor CYP2D6 metabolizers, MDL concentrations were undetectable and the mean MMDL AUC was significantly higher than the MMDL AUC seen in extensive CYP2D6 metabolizers (9,471 nmol.hr/L vs 148 nmol.hr/L).<sup>1</sup><br><br>The contributions of each metabolite (MMDL and MDL) to the efficacy and toxicity of nicergoline is unknown. Use of strong CYP2D6 inhibitors will likely result in increased MMDL concentrations and decreased/negligible MDL concentrations but the clinical effects of this pharmacokinetic alteration are unknown. Patients should be monitored for increased nicergoline toxicities as well as for decreased nicergoline efficacy if these agents are combined.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bottiger Y, Dostert P, Benedetti MS, et al. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. <i>Br J Clin Pharmacol</i>. 1996;42(6):707-711. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8971425\">[PubMed 8971425]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10609":"<p><b>Title</b> Diacerein / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Diacerein. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible, administer diacerein at least 2 hours before or after administration of calcium-, magnesium-, or aluminum-containing antacids.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate<br><b>Exception</b> Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Diacerein Korean product labeling states that doses should be separated by at least 2 hours from calcium-, magnesium-, or aluminum-containing antacids, when possible, due to a potential for diminished diacerein absorption.<sup>1</sup> The mechanism, magnitude, and clinical consequences of this possible interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diacerein [prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198802489. Accessed October 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10610":"<p><b>Title</b> Anticholinergic Agents / Hydrocortisone (Ophthalmic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Hydrocortisone (Ophthalmic) may enhance the adverse/toxic effect of Anticholinergic Agents. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action is required for the majority of patients. Consider increased monitoring of intraocular pressure in patients at high risk for glaucoma or with prolonged ophthalmic hydrocortisone use.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Ophthalmic hydrocortisone prescribing information states that prolonged corticosteroid therapy may increase the risk of intraocular hypertension that may be more likely to occur during treatment with anticholinergics, particularly in patients predisposed to acute angle closure glaucoma.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Siguent Hycor (hydrocortisone) ophthalmic ointment [summary of product characteristics]. St Leonards, New South Wales, Australia: Aspen Pharma Pty Ltd; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10611":"<p><b>Title</b> Tropisetron / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tropisetron. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased tropisetron effects/toxicities if combined with strong CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, the tropisetron (5 mg single oral dose) AUC and maximum serum concentration were 6.8-fold and 1.6-fold higher, respectively, in 6 poor CYP2D6 metabolizers compared with 2 extensive CYP2D6 metabolizers.<sup>1</sup> In a pooled analysis of tropisetron studies of healthy volunteers, the most common adverse events of headache and constipation occurred in 52% and 42% of poor CYP2D6 metabolizers, respectively, but in only 17% of extensive CYP2D6 metabolizers.<sup>2</sup> In a study of cancer patients, extensive CYP2D6 metabolizers had significantly lower tropisetron concentrations and a higher incidence of vomiting compared with poor CYP2D6 metabolizers.<sup>3</sup><br><br>The use of strong CYP2D6 inhibitors is expected to result in increases in tropisetron exposure similar to exposure seen in poor CYP2D6 metabolizers. Tropisetron product labeling states that although exposure to tropisetron is increased in poor metabolizers (or when used with strong CYP2D6 inhibitors), no serious adverse events have been reported and no dose adjustments are required.<sup>4</sup> <br><br>The mechanism of this interaction is inhibition of CYP2D6-mediated tropisetron metabolism by strong CYP2D6 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kim MK, Cho JY, Lim HS, et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. <i>Eur J Clin Pharmacol</i>. 2003;59(2):111-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12728290\">[PubMed 12728290]</a></p>\n<p>2. Kutz K. Pharmacology, toxicology and human pharmacokinetics of tropisetron. <i>Ann Oncol</i>. 1993;4(suppl 3):15-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8363993\">[PubMed 8363993]</a></p>\n<p>3. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. <i>J Clin Oncol</i>. 2002;20(12):2805-2811. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12065557\">[PubMed 12065557]</a></p>\n<p>4. Tropisetron [summary of product characteristics]. Salisbury South, South Australia: Mayne Pharma International Pty Ltd; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10612":"<p><b>Title</b> Tropisetron / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Phenotype</b>: Tropisetron dose adjustments may only be needed in patients who are extensive CYP2D6 metabolizers. Poor CYP2D6 metabolizers are unlikely to have reduced tropisetron concentrations or effects.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced tropisetron effects/therapeutic failure if combined with strong CYP3A4 inducers. Increased doses of tropisetron may be required in extensive metabolizers of CYP2D6.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Tropisetron product labeling states that concomitant use of enzyme-inducing drugs (eg, phenytoin, phenobarbital, carbamazepine, rifampin) and tropisetron may result in increased tropisetron metabolism and reduced tropisetron concentrations and effects.<sup>1</sup> Increased tropisetron doses may be required in patients who are extensive CYP2D6 metabolizers.<sup>1</sup><br><br>In contrast, most available data suggest that tropisetron is primarily metabolized by CYP2D6, an enzyme generally considered to be non-inducible.<sup>1,2,3,4,5</sup> No study has evaluated the effect of enzyme-inducing drugs on tropisetron exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tropisetron [summary of product characteristics]. Salisbury South, South Australia: Mayne Pharma International Pty Ltd; April 2016.</p>\n<p>2. Kim MK, Cho JY, Lim HS, et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. <i>Eur J Clin Pharmacol</i>. 2003;59(2):111-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12728290\">[PubMed 12728290]</a></p>\n<p>3. Kees F, Farber L, Bucher M, Mair G, Morike K, Grobecker H. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2001;52(6):705-707. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11736884\">[PubMed 11736884]</a></p>\n<p>4. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. <i>Drug Metab Dispos</i>. 1996;24(5):602-609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8723743\">[PubMed 8723743]</a></p>\n<p>5. Fischer V, Vickers AE, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. <i>Drug Metab Dispos</i>. 1994;22(2):269-274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8013282\">[PubMed 8013282]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10613":"<p><b>Title</b> GuanFACINE / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider increasing the initial guanfacine dose by up to double in patients receiving moderate CYP3A4 inducers. Consider increasing the guanfacine dose by up to double over 1 to 2 weeks when initiating a moderate CYP3A4 inducer. The guanfacine dosage should be reduced to the target range over 1 to 2 weeks after moderate CYP3A4 inducer discontinuation. Monitor guanfacine response closely, particularly following dose adjustments.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in guanfacine US product labeling, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily for 11 days) decreased the maximum concentration and AUC of guanfacine (4 mg single oral dose) by 56% and 63%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A-mediated guanfacine metabolism. No data are available characterizing the impact of moderate CYP3A4 inducers on guanfacine exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Intuniv (guanfacine) [prescribing information]. Wayne, PA: Shire US Inc; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10614":"<p><b>Title</b> Acetaminophen / Antiemetics (5HT3 Antagonists)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Acetaminophen. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No specific action is required, but be aware that acetaminophen may be less effective in patients treated with 5HT3 antagonists.</p>\n<div>\n <p><b>Antiemetics (5HT3 Antagonists) Interacting Members</b> Alosetron, Dolasetron, Granisetron, Ondansetron, Palonosetron, Ramosetron, Tropisetron</p>\n</div> \n<p><b>Discussion</b> In a cross-over study of 26 healthy volunteers, patients received tropisetron (5 mg single IV dose), granisetron (3 mg single IV dose), and placebo 90 minutes prior to the administration of acetaminophen (1,000 mg single oral dose).<sup>1</sup> Pain scores in response to an electrical stimulation test were recorded before and after each treatment sequence. Pain scores significantly improved after placebo/acetaminophen, but were unchanged after tropisetron/acetaminophen and granisetron/acetaminophen suggesting that the 5HT3 antagonists antagonized the analgesic effect of acetaminophen.<sup>1</sup> In another study of 16 healthy volunteers, both acetaminophen (1,000 mg single IV dose) and tropisetron (5 mg single IV dose) alone improved pain scores in response to an electrical stimulation test. <sup>2</sup> However, the combination of acetaminophen and tropisetron had no effect on pain scores and was similar to that of placebo.<sup>2</sup> In a study of 69 children undergoing tonsillectomy, in addition to a standardized dose of acetaminophen (15 mg/kg single IV dose) patients were randomized to receive either ondansetron (0.1 mg/kg single IV dose) or droperidol (0.05 mg/kg single IV dose) at the start of surgery.<sup>3</sup> Postoperative pain was controlled with IV morphine in the recovery room and additional acetaminophen, niflumic acid, and codeine on the hospital ward.<sup>3</sup> Pain scores did not differ between groups at any time point, but morphine use occurred more frequently in the ondansetron group compared with the droperidol group (57.1% vs 20.6%; <i>P</i> = 0.008).<sup>3</sup> In a randomized controlled study of patients undergoing middle ear surgery, the combination of tropisetron (5 mg single IV dose) and acetaminophen (1,000 mg single IV dose) given at the end of surgery resulted in postoperative pain scores that were numerically higher, but not statistically different, from those of patients who received acetaminophen and placebo.<sup>4</sup><br><br>In contrast, other studies have concluded that the analgesic effect of acetaminophen was either unchanged or improved with the addition of ondansetron.<sup>5,6</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but acetaminophen may exert its analgesic effect by stimulating serotonergic receptors, including the 5HT3 receptor.<sup>1</sup> Thus, administration of 5HT3 antagonists may blunt the analgesic effects of acetaminophen.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pickering G, Loriot MA, Libert F, Eschalier A, Beaune P, Dubray C. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. <i>Clin Pharmacol Ther</i>. 2006;79(4):371-378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16580905\">[PubMed 16580905]</a></p>\n<p>2. Bandschapp O, Filitz J, Urwyler A, Koppert W, Ruppen W. Tropisetron blocks analgesic action of acetaminophen: a human pain model study. <i>Pain</i>. 2011;152(6):1304-1310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21420788\">[PubMed 21420788]</a></p>\n<p>3. Ramirez L, Cros J, Marin B, et al. Analgesic interaction between ondansetron and acetaminophen after tonsillectomy in children: the Paratron randomized, controlled trial. <i>Eur J Pain</i>. 2015;19(5):661-668. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25181557\">[PubMed 25181557]</a></p>\n<p>4. Pickering G, Faure M, Commun F, et al. Tropisetron and paracetamol association in post-operative patients. <i>Fundam Clin Pharmacol</i>. 2012;26(3):432-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395680\">[PubMed 21395680]</a></p>\n<p>5. Bhosale UA, Khobragade R, Naik C, Yegnanarayan R, Kale J. Randomized, double-blind, placebo-controlled study to investigate the pharmacodynamic interaction of 5-HT3 antagonist ondansetron and paracetamol in postoperative patients operated in an ENT department under local anesthesia. <i>J Basic Clin Physiol Pharmacol</i>. 2015;26(3):217-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25324445\">[PubMed 25324445]</a></p>\n<p>6. Jokela R, Ahonen J, Seitsonen E, Marjakangas P, Korttila K. The influence of ondansetron on the analgesic effect of acetaminophen after laproscopic hysterectomy. <i>Clin Pharmacol Ther</i>. 2010;87(6):672-678. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20220746\">[PubMed 20220746]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10621":"<p><b>Title</b> Methemoglobinemia Associated Agents / Tetracaine (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tetracaine (Topical) may enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for signs of methemoglobinemia (eg, hypoxia, cyanosis) when topical tetracaine is used in combination with other agents associated with development of methemoglobinemia.</p>\n<div>\n <p><b>Methemoglobinemia Associated Agents Interacting Members</b> Acetaminophen, Amyl Nitrite, Benzocaine, Celecoxib, Chloroquine, Dapsone (Systemic), Dapsone (Topical), Flutamide, Isosorbide Dinitrate, Isosorbide Mononitrate, Lidocaine (Systemic), Lidocaine (Topical), Mafenide, Metoclopramide, Nicorandil, Nitric Oxide, Nitrofurantoin, Nitroglycerin, Nitroprusside, Phenazopyridine, PHENobarbital, Phenytoin, Prilocaine, Primaquine, Propacetamol, QuiNINE, Sodium Nitrite, SulfADIAZINE, Sulfamethoxazole, SulfaSALAzine, Tetracaine (Topical), Zopiclone</p>\n</div> \n<p><b>Discussion</b> The prescribing information for topical tetracaine products warns about the potential for development of methemoglobinemia during treatment, particularly when used in combination with other methemoglobinemia associated agents.<sup>1,2,3</sup> According to the prescribing information, methemoglobinemia has been reported with use of topical tetracaine.<sup>1,2,3</sup> Patients at increased risk of clinically significant methemoglobinemia include those with glucose-6-phosphate deficiencies and those with congenital or idiopathic methemoglobinemia.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016.</p>\n<p>2. Synera (lidocaine and tetracaine) topical patch [prescribing information]. Souderton, PA: Galen US Inc; March 2014.</p>\n<p>3. Pliaglis (lidocaine and tetracaine) cream [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10622":"<p><b>Title</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction only applies to the extended-release ombitasvir/paritaprevir/ritonavir/dasabuvir product. No interaction with alcohol is expected when using the immediate-release ombitasvir/paritaprevir/ritonavir/dasabuvir product.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may diminish the therapeutic effect of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid alcohol consumption within 4 hours of taking the extended-release ombitasvir/paritaprevir/ritonavir/dasabuvir product. This interaction does not apply to the immediate-release ombitasvir/paritaprevir/ritonavir/dasabuvir product.</p> \n<p><b>Discussion</b> Prescribing information for the extended-release ombitasvir/paritaprevir/ritonavir/dasabuvir product states that in order to ensure the optimal release of dasabuvir, alcohol should not be consumed within 4 hours of taking the extended-release ombitasvir/paritaprevir/ritonavir/dasabuvir product.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira XR (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10623":"<p><b>Title</b> Antihepaciviral Combination Products / Nevirapine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: International labeling states that this combination is contraindicated, while this potential interaction is not listed in US labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Nevirapine may decrease the serum concentration of Antihepaciviral Combination Products. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action is required per US labeling. International labeling states that the use of antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) with nevirapine is contraindicated.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> US and international labeling both state that the use of antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) with moderate CYP3A4 inducers is contraindicated.<sup>1,2,3,4,5</sup> Canadian labeling lists nevirapine as a moderate CYP3A4 inducer and states that use with nevirapine is contraindicated.<sup>4,5</sup> US labeling however, does not list nevirapine as a moderate CYP3A4 inducer, and does not list the combination of antihepaciviral combination products and nevirapine as a potential drug interaction.<sup>1,2,3</sup> <br><br>Available data suggest that nevirapine is a weak CYP3A4 inducer.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Viekira XR (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2016.</p>\n<p>4. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p>5. Technivie (ombitasvir/paritaprevir/ritonavir) [product monograph]. Saint-Laurent, Quebec, Canada: AbbVie Corporation; October 2015.</p>\n<p>6. Viramune XR (nevirapine) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; January 2014.</p>\n<p>7. Mouly S, Rizzo-Padoin N, Simoneau G, et al. Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. <i>Br J Clin Pharmacol</i>. 2006;62(2):200-209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16842395\">[PubMed 16842395]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10624":"<p><b>Title</b> Magnesium Salts / Doxercalciferol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Doxercalciferol may enhance the hypermagnesemic effect of Magnesium Salts. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> The doxercalciferol product labeling warns against the combined use of magnesium products and doxercalciferoll, due to the risk for developing hypermagnesemia.<sup>1</sup> This is based mostly on the known actions of calcitriol (the active metabolite of doxercalciferol) on magnesium absorption and elimination. Studies in humans<sup>2</sup> and rats<sup>3</sup> have shown that calcitriol stimulates magnesium absorption in the intestine<sup>2</sup> and colon.<sup>3</sup> Studies in mouse distal convoluted tubule cells have also shown that calcitriol stimulates magnesium uptake in these cells,<sup>4</sup> which are known to play an important role in magnesium reabsorption.<br><br>The population likely to be at the greatest risk for developing hypermagnesemia due to this interaction are those with chronic renal failure and/or those on chronic dialysis, given alterations in magnesium, calcium, and phosphorous handling common in such patients. Though magnesium salts are generally considered to have no advantage over other phosphate binders in these patients,<sup>5</sup> reports of successful combined use of magnesium products and calcitriol in both chronic renal failure<sup>6</sup> and chronic hemodialysis patients<sup>7</sup> do exist.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hectoral (doxercalciferol) injection [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016.</p>\n<p>2. Ruggiero M, Brunese M, Morelli S, Salvia PF, Mangoni C, Stefano S. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. <i>Boll Soc Ital Biol Sper</i>. 1981;57(7):791-797. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6895034\">[PubMed 6895034]</a></p>\n<p>3. Karbach U, Ewe K. Calcium and magnesium transport and influence of 1,25-dihydroxyvitamin D3. In vivo perfusion study at the colon of the rat. <i>Digestion</i>. 1987;37(1):35-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3609503\">[PubMed 3609503]</a></p>\n<p>4. Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: modulation by extracellular Ca2+ and Mg2+. <i>Am J Physiol Renal Physiol</i>. 2001;280(5):F868-F878. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11292630\">[PubMed 11292630]</a></p>\n<p>5. Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. <i>Drug Saf</i>. 2003;26(15):1093-1115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14640773\">[PubMed 14640773]</a></p>\n<p>6. Lindeman RD. Chronic renal failure and magnesium metabolism. <i>Magnesium</i>. 1986;5(5-6):293-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3807422\">[PubMed 3807422]</a></p>\n<p>7. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. <i>Kidney Int</i>. 1996;49(1):163-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8770963\">[PubMed 8770963]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10625":"<p><b>Title</b> Doxercalciferol / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxercalciferol effects (eg, hypercalcemia, subtherapeutic intact PTH, elevated 25-hydroxyvitamin D levels) if combined with a strong CYP3A4 inducer. Decreased doxercalciferol doses may be required.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Doxercalciferol prescribing information states that phenobarbital or strong CYP3A4 inducers may increase the formation of calcitriol, the active metabolite of doxercalciferol.<sup>1</sup> Dose adjustments of doxercalciferol may be required, and serum total 25-hydroxyvitamin D, intact PTH, and serum calcium concentrations should be closely monitored if therapy with strong CYP3A4 inducers is initiated or discontinued.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hectoral (doxercalciferol) injection [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10626":"<p><b>Title</b> Doxercalciferol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Doxercalciferol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased doxercalciferol effects (eg, elevated intact PTH, subtherapeutic 25-hydroxyvitamin D levels) if combined with a strong CYP3A4 inhibitor. Increased doxercalciferol doses may be required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Doxercalciferol prescribing information states that ketoconazole or strong CYP3A4 inhibitors may reduce the formation of calcitriol, the active metabolite of doxercalciferol.<sup>1</sup> Dose adjustments of doxercalciferol may be required, and serum total 25-hydroxyvitamin D, intact PTH, and serum calcium concentrations should be closely monitored if therapy with strong CYP3A4 inhibitors is initiated or discontinued.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hectoral (doxercalciferol) injection [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10627":"<p><b>Title</b> Alpha1-Agonists / Beta-Blockers (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Beta-Blockers (Nonselective) may enhance the hypertensive effect of Alpha1-Agonists. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Alpha1-Agonists Interacting Members</b> Midodrine, Naphazoline (Nasal), Naphazoline (Ophthalmic), Oxymetazoline (Nasal), Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic), Phenylephrine (Topical), Propylhexedrine, Xylometazoline</p>\n <p><b>Beta-Blockers (Nonselective) Interacting Members</b> Arotinolol, Carteolol (Ophthalmic), Carvedilol, Labetalol, Levobunolol, Metipranolol, Nadolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n</div> \n<p><b>Discussion</b> One case report describes a 49-year old hypertensive woman taking propranolol (40 mg four times daily) who experienced an acute rise in blood pressure (200/108 mm Hg) and a ruptured aneurysm leading to death after instillation of phenylephrine eye drops.<sup>1</sup> She had received phenylephrine eye drops on 2 previous occasions without propranolol, and had experienced no adverse events.<sup>1</sup><br><br>In contrast to this case report, 2 controlled studies concluded that the addition of propranolol to intravenous phenylephrine did not increase the hypertensive response when compared to that with phenylephrine alone.<sup>2,3</sup> In another study, the hypertensive effects of intranasal phenylephrine were unchanged by concomitant use of metoprolol.<sup>4</sup><br><br>Prescribing information for the oxymetazoline/tetracaine nasal spray states that its use should be avoided in patients taking non-selective beta blockers due to the risk of hypertension.<sup>5</sup><br><br>The mechanism of this potential interaction is that when the beta-2 receptors responsible for smooth muscle relaxation are antagonized by non-selective beta blockers, the alpha-1 mediated vasoconstriction may be unopposed, leading to a more pronounced or severe hypertensive effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cass E, Kadar D, Stein HA. Hazards of phenylephrine topical medication in persons taking propranolol. <i>Can Med Assoc J</i>. 1979;120(10):1261-1262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=221086\">[PubMed 221086]</a></p>\n<p>2. Grum DF, Azmy SS. Does propranolol alter the vascular response to phenylephrine before or during halothane anaesthesia in patients with coronary artery disease? <i>Can J Anaesth</i>. 1992;39(1):41-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1733532\">[PubMed 1733532]</a></p>\n<p>3. Myers MG. Beta adrenoceptor antagonism and pressor response to phenylephrine. <i>Clin Pharmacol Ther</i>. 1984;36(1):57-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734050\">[PubMed 6734050]</a></p>\n<p>4. Myers MG, Iazzetta JJ. Intranasally administered phenylephrine and blood pressure. <i>Can Med Assoc J</i>. 1982;127(5):365-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7104913\">[PubMed 7104913]</a></p>\n<p>5. Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10628":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Lixisenatide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lixisenatide may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer oral contraceptives 1 hour before or at least 11 hours after administration of lixisenatide.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> In pharmacokinetic studies described in the lixisenatide prescribing information, administration of an oral contraceptive (ethinyl estradiol 0.03 mg/levonorgestrel 0.15 mg) 1 hour or 4 hours after lixisenatide (10 mcg) had no effect on the AUC or half-life of ethinyl estradiol or levonorgestrel.<sup>1</sup> However, the maximum serum concentration (Cmax) of ethinyl estradiol was decreased 52% and 39%, respectively, and the Cmax of levonorgestrel was decreased 46% and 20%, respectively. When the oral contraceptive was administered 1 hour before or 11 hours after lixisenatide, the was no change in Cmax or AUC of ethinyl estradiol or levonorgestrel.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is delayed oral contraceptive absorption due to lixisenatide-associated reductions in gastric emptying rate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Adlyxin (lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10629":"<p><b>Title</b> Progestins (Contraceptive) / Lixisenatide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lixisenatide may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer oral contraceptives 1 hour before or at least 11 hours after administration of lixisenatide.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> In pharmacokinetic studies described in the lixisenatide prescribing information, administration of an oral contraceptive (ethinyl estradiol 0.03 mg/levonorgestrel 0.15 mg) 1 hour or 4 hours after lixisenatide (10 mcg) had no effect on the AUC or half-life of ethinyl estradiol or levonorgestrel.<sup>1</sup> However, the maximum serum concentration (Cmax) of ethinyl estradiol was decreased 52% and 39%, respectively, and the Cmax of levonorgestrel was decreased 46% and 20%, respectively. When the oral contraceptive was administered 1 hour before or 11 hours after lixisenatide, the was no change in Cmax or AUC of ethinyl estradiol or levonorgestrel.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is delayed oral contraceptive absorption due to lixisenatide-associated reductions in gastric emptying rate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Adlyxin (lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10630":"<p><b>Title</b> Ferric Hydroxide Polymaltose Complex / Angiotensin-Converting Enzyme Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction applies only to the intravenous administration of ferric hydroxide polymaltose complex.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased risk of anaphylactic-type reactions if these agents are combined.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Ferric hydroxide polymaltose complex product labeling states that patients receiving an angiotensin-converting enzyme (ACE) inhibitor may be at greater risk for anaphylactic-type reactions (eg, erythema, nausea, vomiting, hypotension).<sup>1</sup> Patients should be monitored for these effects if these agents are combined. <br><br>The specific mechanism for this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ferrosig (ferric hydroxide polymaltose complex) [summary of product characteristics]. Rowville, Victoria, Australia: Sigma Company Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10631":"<p><b>Title</b> Iron Salts / Ferric Hydroxide Polymaltose Complex</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction applies only to the intravenous administration of ferric hydroxide polymaltose complex.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ferric Hydroxide Polymaltose Complex may decrease the serum concentration of Iron Salts. Specifically, the absorption of oral iron salts may be reduced. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron salts. Therapy with oral iron salts should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Hydroxide Polymaltose Complex, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Citrate, Ferric Gluconate, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> Ferric hydroxide polymaltose complex product labeling states that it should not be administered concomitantly with oral iron preparations as the absorption of oral iron is reduced.<sup>1</sup> Oral iron therapy should not begin until at least 1 week after the last ferric hydroxide polymaltose complex injection.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ferrosig (ferric hydroxide polymaltose complex) [summary of product characteristics]. Rowville, Victoria, Australia: Sigma Company Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10632":"<p><b>Title</b> Ergot Derivatives / Minocycline</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Minocycline may enhance the adverse/toxic effect of Ergot Derivatives. Specifically, the risk of ergotism may be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Cabergoline, Dihydroergotamine, Ergoloid Mesylates, Ergonovine, Ergotamine, Methylergonovine, Nicergoline, Pergolide</p>\n</div> \n<p><b>Discussion</b> Minocycline prescribing information states that there may be an increased risk of ergotism when ergot alkaloids or their derivatives are given with tetracyclines.<sup>1</sup> Prescribing information for other available tetracycline antibiotics (ie, tetracycline, demeclocyline, doxycycline) does not warn of this potential interaction.<sup>2,3,4</sup> No cases of ergotism due to the combination of ergot derivatives and tetracyclines have been published in English and a mechanism by which these agents may interact has not been identified or proposed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Minocin (minocycline) [prescribing information]. Parsippany, NJ: The Medicines Company; April 2015.</p>\n<p>2. Demeclocycline [prescribing information]. Middlesex, NJ: CorePharma LLC; August 2012.</p>\n<p>3. Doxycycline [prescribing information]. Spring Valley, NY: PAR Pharmaceutical Companies Inc; February 2014.</p>\n<p>4. Tetracycline [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10633":"<p><b>Title</b> Arbekacin / Dextran</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dextran may enhance the nephrotoxic effect of Arbekacin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of arbekacin and dextran when possible. If concurrent use is necessary, monitor closely for evidence of nephropathy and stop concurrent use if nephropathy occurs.</p> \n<p><b>Discussion</b> The arbekacin prescribing information recommends avoiding concurrent use with dextran due to the risk of nephropathy.<sup>1</sup><br><br>Specific data concerning the risks associated with the combination are not provided, but aminoglycosides such as arbekacin have been associated with an increased risk for nephrotoxicity suggesting a potential risk for increased nephrotoxicity with others drugs associated with nephropathy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Habekacin injection (arbekacin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200000390. Accessed April, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10634":"<p><b>Title</b> Arbekacin / Pentastarch</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pentastarch may enhance the nephrotoxic effect of Arbekacin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of arbekacin and hydroxyethyl starch (such as pentastarch) when possible. If concurrent use is necessary, monitor closely for evidence of nephropathy and stop concurrent use if nephropathy occurs.</p> \n<p><b>Discussion</b> The arbekacin prescribing information recommends avoiding concurrent use with hydroxyethyl starch (such as pentastarch) due to the risk of nephropathy.<sup>1</sup><br><br>Specific data concerning the risks associated with the combination are not provided, but aminoglycosides such as arbekacin have been associated with an increased risk for nephrotoxicity suggesting a potential risk for increased nephrotoxicity with others drugs associated with nephropathy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Habekacin injection (arbekacin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200000390. Accessed April, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10635":"<p><b>Title</b> Arbekacin / Tetrastarch</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tetrastarch may enhance the nephrotoxic effect of Arbekacin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of arbekacin and hydroxyethyl starch (such as tetrastarch) when possible. If concurrent use is necessary, monitor closely for evidence of nephropathy and stop concurrent use if nephropathy occurs.</p> \n<p><b>Discussion</b> The arbekacin prescribing information recommends avoiding concurrent use with hydroxyethyl starch (such as tetrastarch) due to the risk of nephropathy.<sup>1</sup><br><br>Specific data concerning the risks associated with the combination are not provided, but aminoglycosides such as arbekacin have been associated with an increased risk for nephrotoxicity suggesting a potential risk for increased nephrotoxicity with others drugs associated with nephropathy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Habekacin injection (arbekacin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200000390. Accessed April, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10636":"<p><b>Title</b> Arbekacin / Hetastarch</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Hetastarch may enhance the nephrotoxic effect of Arbekacin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of arbekacin and hydroxyethyl starch (such as hetastarch) when possible. If concurrent use is necessary, monitor closely for evidence of nephropathy and stop concurrent use if nephropathy occurs.</p> \n<p><b>Discussion</b> The arbekacin prescribing information recommends avoiding concurrent use with hydroxyethyl starch (such as hetastarch) due to the risk of nephropathy.<sup>1</sup><br><br>Specific data concerning the risks associated with the combination are not provided, but aminoglycosides such as arbekacin have been associated with an increased risk for nephrotoxicity suggesting a potential risk for increased nephrotoxicity with others drugs associated with nephropathy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Habekacin injection (arbekacin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200000390. Accessed April, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10637":"<p><b>Title</b> Aminoglycosides / Arbekacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Arbekacin may enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of nephrotoxicity or ototoxicity with use of this combination.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> The arbekacin prescribing information cautions that concurrent use with other aminoglycoside antibiotics may result in an increased risk for nephrotoxicity or ototoxicity, both of which are known adverse effects of these drugs.<sup>1</sup> Such combined use of more than one aminoglycoside could result in an increased risk for any such aminoglycoside toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Habekacin injection (arbekacin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200000390. Accessed April, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10655":"<p><b>Title</b> Timolol (Ophthalmic) / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Ophthalmic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of systemic beta-blocker effects, including but not limited to orthostatic hypotension, bradycardia, and exercise intolerance.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The AUC and maximum serum concentrations of timolol were increased by 1.6- to 1.8-fold and 1.5-fold, respectively, with concurrent administration of the strong CYP2D6 inhibitor paroxetine in a study of 12 healthy volunteers who received timolol ophthalmic drops (0.5%) or ophthalmic gel (0.1%) together with paroxetine 20 mg/day.<sup>1</sup> No patients receiving the 0.1% gel had serum timolol concentrations greater than 0.7 ng/mL, which is considered the threshold above which systemic adverse effects would be expected, but 6/12 patients receiving the 0.5% drops had serum concentrations exceeding 0.7 ng/mL with concurrent paroxetine. Similarly, none of the patients receiving the 0.1% gel had evidence of systemic adverse effects, but among patients receiving the 0.5% drops, the standing heart rate at 1 and 3 hours after administration was significantly lower with concurrent paroxetine. In a separate study of 6 healthy volunteers, concurrent use of timolol (0.25 mg IV) with the strong CYP2D6 inhibitor quinidine (100 mg) was associated with 10% to 30% higher timolol concentrations and 10% to 40% greater beta-blockade (measured as isoproterenol sensitivity).<sup>2</sup> The authors concluded that timolol concentrations of less than 1 ng/mL produce measurable beta-blocking effects.<br><br>The likely mechanism for this interaction is inhibition of timolol metabolism by CYP2D6, resulting in increases timolol concentrations. In vitro data show that CYP2D6 is primarily responsible for timolol metabolism and that strong CYP2D6 inhibitors can interfere with this metabolism.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Maenpaa J, Volotinen-Maja M, Kautiainen H, et al. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops. <i>Drug Metab Dispos</i>. 2014;42(12):2068-2076. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25261563\">[PubMed 25261563]</a></p>\n<p>2. Kaila T, Huupponen R, Karhuvaara S, et al. Beta-blocking effects of timolol at low plasma concentrations. <i>Clin Pharmacol Ther</i>. 1991;49(1):53-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1846331\">[PubMed 1846331]</a></p>\n<p>3. Volotinen M, Korjamo T, Tolonen A, et al. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. <i>Basic Clin Pharmacol Toxicol</i>. 2010;106(4):302-309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19912165\">[PubMed 19912165]</a></p>\n<p>4. Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Maenpaa J, Pelkonen O. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. <i>Drug Metab Dispos</i>. 2007;35(7):1135-1141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17431033\">[PubMed 17431033]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10656":"<p><b>Title</b> Vitamin K Antagonists / Fat Emulsion (Fish Oil and Plant Based)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fat Emulsion (Fish Oil and Plant Based) may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of diminished anticoagulant response, including a decreased PT/INR, with use of this fat emulsion together with vitamin K antagonist anticoagulants.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but soybean and olive oils, which are components of this fish oil based fat emulsion, contain moderate to high amounts of vitamin K. This product contains 6 g of soybean oil and 5 g of olive oil per 100 mL,<sup>1</sup> which is estimated to provide at least 13 to 15 mcg of vitamin K. Monitor patients for evidence of decreased anticoagulant response (ie, decreased PT/INR) with concurrent use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Smoflipid (fat emulsion, fish oil based) [prescribing information]. Uppsala, Sweden: Fresenius Kabi; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10657":"<p><b>Title</b> Eltrombopag / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may decrease the serum concentration of Eltrombopag. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased eltrombopag effects (ie, monitor platelet counts) for 2 to 3 weeks after initiation of cyclosporine. An increase in eltrombopag dose may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the eltrombopag prescribing information, cyclosporine (200 mg single dose) decreased the eltrombopag (50 mg single dose) AUC and maximum serum concentration (Cmax) 18% and 25%, respectively.<sup>1</sup> Cyclosporine (600 mg single dose) decreased the eltrombopag AUC and Cmax 24% and 39%, respectively.<sup>1,2</sup> <br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Revolade (eltrombopag) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2016.</p>\n<p>2. Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10658":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Pelubiprofen</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pelubiprofen may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of pelubiprofen and other nonsteroidal anti-inflammatory drugs (NSAIDS).</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Product labeling for pelubiprofen states that administration of pelubiprofen with other NSAIDs should be avoided due to the risk for increased adverse effects and toxicities.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pelubi (pelubiprofen) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200704590. Accessed May 14, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10659":"<p><b>Title</b> Warfarin / Bifonazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bifonazole may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased warfarin response (increased INR, signs/symptoms of bleeding) when topical bifonazole is initiated in a patient on warfarin, especially if applied to large body surface areas, under occlusion, or to broken or damaged skin.</p> \n<p><b>Discussion</b> Bifonazole product labeling states that based on limited data, an interaction between topical bifonazole and warfarin may be possible, leading to increases in INR.<sup>1</sup> If bifonazole is used in a patient on warfarin therapy, they should be appropriately monitored, especially if bifonazole is applied to large body surface area, under occlusion, or to broken or damaged skin.<sup>1</sup><br><br>The likely mechanism of this reported interaction is bifonazole-mediated inhibition of CYP450 isoenzymes involved in warfarin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Canesten (bifonazole) [summary of product characteristics]. Newbury, Berkshire, UK: Bayer PLC; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10660":"<p><b>Title</b> Sirolimus / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations and effects during concomitant use. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 14 healthy volunteers, the maximum serum concentration and AUC of sirolimus (20 mg single oral dose given on day 9) decreased 71% and 82%, respectively, when co-administered with the strong CYP3A4 inducer rifampin (600 mg daily for 14 days).<sup>1,2</sup> A pharmacokinetic evaluation in a liver transplant recipient receiving sirolimus and phenytoin found that the sirolimus AUC, minimum serum concentration, and half-life increased 1.7-fold, 3.8-fold, and 2.2-fold, respectively, 10 days after phenytoin discontinuation.<sup>3</sup> Case reports describe transplant recipients treated with sirolimus who required 4-fold to 6-fold increases in their sirolimus dose after initiation of rifampin (when given as part of a multidrug regimen to treat tuberculosis)<sup>4</sup> or phenytoin.<sup>5</sup> Another report describes a renal transplant recipient in whom therapeutic sirolimus levels were not achieved while receiving concurrent phenytoin, despite a 10-fold sirolimus dose increase.<sup>6</sup><br> <br>Sirolimus prescribing information states that concomitant use of sirolimus with strong CYP3A4 inducers should be avoided if possible and alternative agents with less potential for interaction should be considered.<sup>1</sup><br> <br>The mechanism of this interaction is likely induction of CYP3A4 and P-glycoprotein, an enzyme and transporter involved in sirolimus metabolism and disposition, by strong CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, November 2015.</p>\n<p>2. Tortorici MA, Matschke K, Korth-Bradley JM, DiLea C, Lasseter KC. The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers. <i>Clin Pharmacol Drug Dev</i>. 2014;3(1):51-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27128230\">[PubMed 27128230]</a></p>\n<p>3. Fridell JA, Jain AK, Patel K, et al. Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report. <i>Ther Drug Monit</i>. 2003;25(1):117-119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12548156\">[PubMed 12548156]</a></p>\n<p>4. Ngo BT, Pascoe M, Khan D. Drug interaction between rifampicin and sirolimus in transplant patients. <i>Saudi J Kidney Dis Transpl</i>. 2011;22(1):112-115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21196624\">[PubMed 21196624]</a></p>\n<p>5. Bates D, Burak KW, Coffin CS, Ying T, Enns EM. Phenytoin-induced reduction in sirolimus levels. <i>Can J Hosp Pharm</i>. 2011;64(4):271-274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22479070\">[PubMed 22479070]</a></p>\n<p>6. Hodges CB, Maxwell H, Beattie TJ, Murphy AV, Jindal RM. Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity. <i>Pediatr Nephrol</i>. 2001;16(10):777-778. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11605780\">[PubMed 11605780]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10661":"<p><b>Title</b> Piribedil / Antipsychotic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of piribedil with antiemetic antipsychotics is contraindicated. Other concurrent use is not recommended (except with clozapine, to which this warning specifically does not apply). If use of an antipsychotic is required in a patient receiving piribedil, the piribedil should be gradually withdrawn.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol<br><b>Exception</b> CloZAPine</p>\n</div> \n<p><b>Discussion</b> The piribedil labeling lists concurrent use of antiemetic neuroleptics as contraindicated and concurrent use of antipsychotic neuroleptics (other than clozapine) as unadvisable.<sup>1</sup><br><br>Studies have demonstrated an ability of typical psychotics to inhibit levodopa effects including anti-Parkinson effects,<sup>2</sup> induced involuntary movements,<sup>2</sup> and growth hormone stimulation.<sup>3</sup> Further, two studies have shown reduced induction of prolactin release by atypical antipsychotics with concomitant levodopa.<sup>4,5</sup><br><br>These interactions are likely the consequence of opposing dopaminergic mechanisms of action of the anti-Parkinson dopamine agonists and dopamine antagonist antipsychotics. If possible, antipsychotics should be avoided in combination with dopamine agonists.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trivastal (piribedil) [summary of product characteristics]. Les Laboratories Servier; August 2013.</p>\n<p>2. Tarsy D, Parkes JD, Marsden CD. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. <i>J Neurol Neurosurg Psychiatry</i>. 1975;38(4):331-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1095689\">[PubMed 1095689]</a></p>\n<p>3. Mims RB, Scott CL, Modebe O, et al. Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine. <i>J Clin Endocrinol Metab</i>. 1975;40(2):256-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1117978\">[PubMed 1117978]</a></p>\n<p>4. Delitala G. Stimulating action of sulpiride and pimozide on prolactin release. Effect of bromocriptine, L-dopa, and metergoline administration. <i>Acta Endocrinol (Copenh)</i>. 1977;86(2):251-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=578618\">[PubMed 578618]</a></p>\n<p>5. Vaidya RA, Sheth AR, Aloorkar SD, et al. The inhibitory effect of the cowhage plant-mucuna pruriens-and L-dopa on chlorpromazine-induced hyperprolactinemia. <i>Neurol India</i>. 1978;26(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=753997\">[PubMed 753997]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10662":"<p><b>Title</b> Tetrabenazine / Piribedil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Piribedil may diminish the therapeutic effect of Tetrabenazine. Tetrabenazine may diminish the therapeutic effect of Piribedil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of piribedil with tetrabenazine is considered unadvisable.</p> \n<p><b>Discussion</b> The piribedil labeling describes concurrent use of tetrabenazine as unadvisable due to the risk for both drugs to antagonize one another's effects.<sup>1</sup><br><br>Piribedil is a dopamine agonist, while tetrabenazine works at least in part by diminishing the stimulation of dopamine receptors. Consequently, use of this combination may result in decreased activity of one or both drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trivastal (piribedil) [summary of product characteristics]. Les Laboratories Servier; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10663":"<p><b>Title</b> Piribedil / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the sedative effect of Piribedil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of alcohol with piribedil is not advisable. Advise patients that any concurrent use may result in excessive sedation. Monitor closely for evidence of increased sedative and sleep effects.</p> \n<p><b>Discussion</b> The piribedil labeling describes concurrent use of alcohol as unadvisable due to the risk for increased sedative effects.<sup>1</sup><br><br>Alcohol has strong CNS depressant effects, and piribedil use has been associated with somnolence, sudden sleep onset, and dizziness, all of which may be exacerbated by concurrent alcohol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trivastal (piribedil) [summary of product characteristics]. Les Laboratories Servier; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10664":"<p><b>Title</b> Piribedil / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Piribedil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of increased sedative and sleep effects.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The piribedil labeling recommends caution with concurrent use of other CNS depressants due to the risk for increased sedative and central depressive effects.<sup>1</sup><br><br>Piribedil use has been associated with somnolence, sudden sleep onset, and dizziness, all of which may be exacerbated by concurrent use of other CNS depressants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trivastal (piribedil) [summary of product characteristics]. Les Laboratories Servier; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10665":"<p><b>Title</b> Simvastatin / Niacin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Some non-US labeling state that any concurrent use of simvastatin with lipid-lowering doses of niacin (ie, more than 1 g/day) in Asian patients is not recommended.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Niacin may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Niacin may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Simvastatin and niacin each have the potential to cause muscle toxicity (including rhabdomyolysis) and other toxicities when used as monotherapy, and use of these agents in combination may increase these risks, although the overall risk is likely to remain low in most patients. Monitor patients receiving combination therapy closely for signs and symptoms of toxicity, and consider a dose reduction of simvastatin as appropriate to minimize any risk for toxicity. According to simvastatin prescribing information, the combination of simvastatin 80 mg with niacin doses of 1 g or greater daily should be avoided in Chinese patients, and simvastatin doses over 20 mg/day should be used cautiously in these patients. Whether these cautions apply to other patients of Asian heritage is unknown. Some non-US labeling apply this warning more broadly and state that any concurrent use of simvastatin with lipid-lowering doses of niacin (ie, more than 1 g/day) in Asian patients is not recommended.</p> \n<p><b>Discussion</b> The US labeling both simvastatin and niacin caution that combined therapy can increase the risk of muscle toxicities.<sup>1,2</sup> Additionally, simvastatin US prescribing information states that simvastatin 80 mg should be avoided in Chinese patients receiving lipid-lowering doses of niacin (1 g/day or more),<sup>1</sup> and the Canadian labeling for simvastatin further states that any concurrent use of simvastatin with lipid-lowering doses of niacin is not recommended in Asian patients.<sup>3</sup><br><br>In a clinical trial of 25,673 patients 50 to 80 years old with a history of vascular disease, treatment with simvastatin (40 mg daily, with or without 10 mg ezetimibe daily, depending on LDL) and niacin / laropiprant (1 g / 20 mg daily for 4 weeks, then 2 g / 40 mg daily for 3 to 6 weeks) was associated with an increase in myopathy, gastrointestinal adverse effects, infection, bleeding, new onset diabetes, and disturbed diabetes control compared to simvastatin (+/- ezetimibe) with placebo.<sup>4</sup> The relative risk of myopathy was substantially higher in Chinese study centers than in European centers (5.2 vs. 1.5). More cases of rhabdomyolysis were reported with concurrent simvastatin and niacin (4 cases, 0.2%) than with simvastatin and placebo (1 case, less than 0.1%) in a clinical trial of 3,414 patients given 1.5 to 2 g of extended-release niacin or placebo in addition to simvastatin (40-80 mg/day, with or without ezetimibe 10 mg/day).<sup>5</sup><br><br>Further, the US and Canadian labeling describe modest increases in simvastatin and simvastatin acid concentrations with concurrent niacin, citing 9% to 40% increases in simvastatin AUC and 18% to 60% increases in simvastatin acid AUC with concurrent extended-release niacin 2000 mg/day.<sup>1,3</sup><br><br>The mechanism of this possible interaction is uncertain, but it appears to be a pharmacodynamic interaction resulting from the potential of each agent to independently contribute to the occurrence of muscle and other toxicities. The mechanism of any pharmacokinetic interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015.</p>\n<p>2. Niaspan (niacin extended-release) [prescribing information]. North Chicago, IL: AbbVie Inc.; April 2015.</p>\n<p>3. Zocor (simvastatin) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc.; December 2014.</p>\n<p>4. HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. <i>N Engl J Med</i>. 2014;371(3):203-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25014686\">[PubMed 25014686]</a></p>\n<p>5. AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. <i>N Engl J Med</i>. 2011;365(24):2255-2267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22085343\">[PubMed 22085343]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10666":"<p><b>Title</b> Rosuvastatin / Niacin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Some non-US labeling lists concurrent use of rosuvastatin 40 mg as contraindicated with niacin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Niacin may enhance the myopathic (rhabdomyolysis) effect of Rosuvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Rosuvastatin and niacin each have the potential to cause muscle toxicity (including rhabdomyolysis) and other toxicities when used as monotherapy, and use of these agents in combination may increase these risks, although the overall risk is likely to remain low in most patients. Monitor patients receiving combination therapy closely for signs and symptoms of toxicity, and consider a dose reduction of rosuvastatin as appropriate to minimize any risk for toxicity. Some non-US labeling list concurrent use of rosuvastatin 40 mg as contraindicated with niacin.</p> \n<p><b>Discussion</b> The US labeling both rosuvastatin and niacin caution that combined therapy can increase the risk of muscle toxicities.<sup>1,2</sup> Canadian labeling for rosuvastatin further contraindicates concurrent use of niacin with the higher rosuvastatin 40 mg/day dose.<sup>3</sup> Although specific data concerning this combination is limited, data with the HMG-CoA reductase inhibitors simvastatin and lovastatin address the risks with similar combinations.<br><br>In a clinical trial of 25,673 patients 50 to 80 years old with a history of vascular disease, treatment with simvastatin (40 mg daily, with or without 10 mg ezetimibe daily, depending on LDL) and niacin / laropiprant (1 g / 20 mg daily for 4 weeks, then 2 g / 40 mg daily for 3 to 6 weeks) was associated with an increase in myopathy, gastrointestinal adverse effects, infection, bleeding, new onset diabetes, and disturbed diabetes control compared to simvastatin (+/- ezetimibe) with placebo.<sup>4</sup> The relative risk of myopathy was substantially higher in Chinese study centers than in European centers (5.2 vs. 1.5). More cases of rhabdomyolysis were reported with concurrent simvastatin and niacin (4 cases, 0.2%) than with simvastatin and placebo (1 case, less than 0.1%) in a clinical trial of 3,414 patients given 1.5 to 2 g of extended-release niacin or placebo in addition to simvastatin (40-80 mg/day, with or without ezetimibe 10 mg/day).<sup>5</sup><br><br>A review of adverse events reported to the FDA concluded that the lovastatin-niacin combination product was not associated with significantly more liver or muscle adverse effects than either product used as monotherapy (or than any other HMG-CoA reductase inhibitor).<sup>6</sup> A clinical trial of the combination product in nearly 4,500 patients also reported elevated liver function tests in less than 0.3% of patients and elevations of creatine kinase (marker of muscle damage) in 0.24% of patients.<sup>7</sup> Of note, this study was only of short duration (12 weeks), so caution should be used extrapolating these data to longer-term use of niacin combinations.<br><br>Case reports describe the occurrence of myopathy symptoms (muscle weakness and pain, dark urine, and increased creatine kinase concentrations) in lovastatin-stable patients following the use of niacin doses of at least 1 g daily.<sup>8,9</sup> One patient was also receiving cyclosporine, an agent reported to increase the risk of rhabdomyolysis in patients also receiving HMG-CoA reductase inhibitors.<sup>9</sup><br><br>The mechanism of this possible interaction is uncertain, but it appears to be a pharmacodynamic interaction resulting from the potential of each agent to independently contribute to the occurrence of muscle and other toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2013.</p>\n<p>2. Niaspan (niacin extended-release) [prescribing information]. North Chicago, IL: AbbVie Inc.; April 2015.</p>\n<p>3. Crestor (rosuvastatin) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; July 2014.</p>\n<p>4. HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. <i>N Engl J Med</i>. 2014;371(3):203-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25014686\">[PubMed 25014686]</a></p>\n<p>5. AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. <i>N Engl J Med</i>. 2011;365(24):2255-2267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22085343\">[PubMed 22085343]</a></p>\n<p>6. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration Adverse Event Reporting System). <i>Am J Cardiol</i>. 2007;99(3):379-381. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17261402\">[PubMed 17261402]</a></p>\n<p>7. Rubenfire M; Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. <i>Am J Cardiol</i>. 2004;94(3):306-311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15276093\">[PubMed 15276093]</a></p>\n<p>8. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. <i>Ann Intern Med</i>. 1988;109(7):597-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3421570\">[PubMed 3421570]</a></p>\n<p>9. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. <i>N Engl J Med</i>. 1988;318(1):46-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3275891\">[PubMed 3275891]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10667":"<p><b>Title</b> Tinidazole / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Tinidazole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Tinidazole prescribing information states that strong CYP3A4 inducers may accelerate the elimination of the CYP3A4 substrate tinidazole, resulting in decreased plasma levels of tinidazole.<sup>1</sup> The clinical consequences of reduced tinidazole concentrations are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tindamax (tinidazole) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; May 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10668":"<p><b>Title</b> Tinidazole / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tinidazole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Tinidazole prescribing information states that strong CYP3A4 inhibitors may reduce the elimination of the CYP3A4 substrate tinidazole, resulting in increased plasma levels of tinidazole.<sup>1</sup> The clinical consequences of increased tinidazole concentrations are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tindamax (tinidazole) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; May 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10669":"<p><b>Title</b> Aspirin / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may enhance the antiplatelet effect of Aspirin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased antiplatelet effects of aspirin (eg, increased bruising or bleeding) if combined with nondihydropyridine calcium channel blockers.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil, DilTIAZem, Verapamil</p>\n</div> \n<p><b>Discussion</b> The bleeding time of a patient taking aspirin (650 mg several times per week for several years) was twice as long after initiation of verapamil (80 mg three times daily), with abnormal bruising that resolved after verapamil discontinuation.<sup>1</sup> Verapamil was re-initiated without aspirin and no bleeding or bruising recurred.<sup>1</sup> Another case report describes a patient taking aspirin (325 mg daily) who developed ecchymosis of the extremities and a retroperitoneal bleed approximately 3 weeks after starting verapamil (240 mg daily).<sup>2</sup> Bleeding times also doubled in 5 healthy volunteers given oral diltiazem (60 mg every 8 hours x 7 doses) after aspirin administration (40 mg daily x 3 doses).<sup>3</sup> Other investigations found that the addition of diltiazem or clentiazem to aspirin and ticlopidine therapy resulted in inhibition of thromboxane B<sub>2</sub> production and reduced platelet aggregation when compared with aspirin and ticlopidine therapy alone,<sup>4,5</sup> and inhibition of platelet aggregation by aspirin was enhanced by the addition of diltiazem in another studies.<sup>6</sup> In contrast, 2 studies found that diltiazem or verapamil alone inhibited platelet aggregation,<sup>7,8</sup> but did not enhance the effects of aspirin, reduce thromboxane B<sub>2</sub> levels, or prolong bleeding times.<sup>8</sup> <br><br>Verapamil prescribing information states that cases of increased bleeding have been reported with verapamil and aspirin coadministration.<sup>9</sup><br><br>The mechanism of these interactions are unknown, although it has been hypothesized that calcium channel blockers inhibit thromboxane B<sub>2</sub> production and/or interfere with platelet calcium metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ring ME, Martin GV, Fenster PE. Clinically significant antiplatelet effects of calcium-channel blockers. <i>J Clin Pharmacol</i>. 1986;26(8):719-720. [PubMed 3793966]</p>\n<p>2. Verzino E, Kaplan B, Ashley JV, Burdette M. Verapamil-aspirin interaction. <i>Ann Pharmacother</i>. 1994;28(4):536-537. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8038482\">[PubMed 8038482]</a></p>\n<p>3. Ring ME, Corrigan JJ Jr, Fenster PE. Effects of oral diltiazem on platelet function: alone and in combination with low dose aspirin. <i>Thromb Res</i>. 1986;44(3):391-400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3798404\">[PubMed 3798404]</a></p>\n<p>4. Dai H, Chen J, Tao Q, et al. Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty. <i>Postgrad Med J</i>. 2003;79(935):522-526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13679549\">[PubMed 13679549]</a></p>\n<p>5. Odawara A, Katoh M, Karasawa T, Tamura K, Sasaki Y. Inhibitory effect of clentiazem (TA-3090) on platelet aggregation - alone or in combination with aspirin or ticlopidine. <i>Thromb Res</i>. 1994;75(2):109-119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7974385\">[PubMed 7974385]</a></p>\n<p>6. Altman R, Scazziota A, Dujovne C. Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation. <i>Clin Pharmacol Ther</i>. 1988;44(3):320-325. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3416553\">[PubMed 3416553]</a></p>\n<p>7. L-Lacoste L, Lam JY, Hung J, Waters D. Oral verapamil inhibits platelet thrombus formation in humans. <i>Circulation</i>. 1994;89(2):630-634. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8313551\">[PubMed 8313551]</a></p>\n<p>8. Zucker ML, Budd SE, Dollar LE, Chernoff SB, Altman R. Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists. <i>Thromb Haemost</i>. 1993;70(2):332-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8236144\">[PubMed 8236144]</a></p>\n<p>9. Calan (verapamil) [prescribing information]. New York, NY: G.D. Searle; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10670":"<p><b>Title</b> Nitroprusside / Blood Pressure Lowering Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> While the concomitant use of nitroprusside with other blood pressure lowering agents is often clinically appropriate, patients should be monitored closely for additive hypotensive effects. A significantly reduced nitroprusside dose may be adequate to produce the desired blood pressure lowering effects.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> In a study of 10 surgery patients, coadministration of a diltiazem infusion with nitroprusside reduced nitroprusside dose requirements by 55%.<sup>1</sup> Nitroprusside prescribing information states that the hypotensive effect of nitroprusside is augmented by most other hypotensive drugs.<sup>2</sup> The mechanism is likely related to additive vasodilatory effects of the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bernard JM, Moren J, Demeure D, Hommeril JL, Passuti N, Pinaud M. Diltiazem reduces the dose requirement for nitroprusside-induced hypotension. <i>Anesth Analg</i>. 1993;77(2):318-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8346832\">[PubMed 8346832]</a></p>\n<p>2. Nitropress (nitroprusside) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10671":"<p><b>Title</b> Vinflunine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of vinflunine and strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in vinflunine product labeling, ketoconazole (400 mg daily x 8 days) increased the AUC of vinflunine and 4-O-deacetylvinflunine (an active metabolite of vinflunine) 30% and 50%, respectively.<sup>1</sup><br><br>Vinflunine product labeling states that concomitant use of vinflunine and strong CYP3A4 inhibitors should be avoided.<sup>1</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for vinflunine metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p>2. Zhao XP, Zhong J, Liu XQ, Wang GJ. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. <i>Acta Pharmacol Sin</i>. 2007;28(1):118-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17184591\">[PubMed 17184591]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10672":"<p><b>Title</b> Vinflunine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of vinflunine and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> No study has evaluated the concomitant use of vinflunine and strong CYP3A4 inducers. However, because vinflunine is a substrate of CYP3A4, vinflunine product labeling states that combined use should be avoided due to the risk for reduced vinflunine concentrations and effects.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p>2. Zhao XP, Zhong J, Liu XQ, Wang GJ. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. <i>Acta Pharmacol Sin</i>. 2007;28(1):118-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17184591\">[PubMed 17184591]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10673":"<p><b>Title</b> Vinflunine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Vinflunine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The vinflunine product labeling states that patients should not drink grapefruit juice (GFJ) during vinflunine therapy, which is a theoretical interaction based on the potential for GFJ to inhibit CYP3A4, an important enzyme involved in the metabolism of vinflunine.<sup>1,2</sup> However, several studies examining the drug interaction potential of GFJ have concluded that GFJ primarily inhibits intestinal CYP3A, having little or no impact on hepatic CYP3A activity,<sup>3,4,5,6</sup> suggesting that this interaction is likely of little consequence for injected medications, such as vinflunine. In fact studies with the CYP3A substrates felodipine and midazolam both reported significant interactions between GFJ and orally administered drug but not with IV felodipine or IV midazolam.<sup>3,4</sup> One possible exception to this may be with consumption of very high amounts of GFJ. Patients (n=8) consuming 8 ounces of double-strength GFJ 3 times a day for 3 days reportedly had an 18% reduction in the erythromycin breath test (a surrogate marker of hepatic CYP3A activity).<sup>7</sup> In this same study, however, consumption of a single 8 ounce serving of double-strength or single-strength GFJ had little impact on the erythromycin breath test.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p>2. Zhao XP, Zhong J, Liu XQ, Wang GJ. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. <i>Acta Pharmacol Sin</i>. 2007;28(1):118-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17184591\">[PubMed 17184591]</a></p>\n<p>3. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. <i>Eur J Clin Pharmacol</i>. 1997;52(2):139-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9174684\">[PubMed 9174684]</a></p>\n<p>4. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. <i>Clin Pharmacol Ther</i>. 1995;58(1):20-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7628179\">[PubMed 7628179]</a></p>\n<p>5. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. <i>J Clin Invest</i>. 1997;99(10):2545-2553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9153299\">[PubMed 9153299]</a></p>\n<p>6. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. <i>Clin Pharmacol Ther</i>. 2003;74(2):121-129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12891222\">[PubMed 12891222]</a></p>\n<p>7. Veronese ML, Gillen LP, Burke JP, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. <i>J Clin Pharmacol</i>. 2003;43(8):831-839. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12953340\">[PubMed 12953340]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10674":"<p><b>Title</b> Vinflunine / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Vinflunine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of vinflunine and St John's wort.</p> \n<p><b>Discussion</b> No study has evaluated the concomitant use of vinflunine and St John's wort or any CYP3A4 inducer. However, because vinflunine is a substrate of CYP3A4, vinflunine product labeling states that the combined use of vinflunine and St John's wort should be avoided due to the risk for reduced vinflunine concentrations and effects.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p>2. Zhao XP, Zhong J, Liu XQ, Wang GJ. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. <i>Acta Pharmacol Sin</i>. 2007;28(1):118-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17184591\">[PubMed 17184591]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10675":"<p><b>Title</b> Vinflunine / DOXOrubicin (Conventional)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DOXOrubicin (Conventional) may enhance the adverse/toxic effect of Vinflunine. Specifically, the risk for hematologic toxicities may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities if vinflunine and doxorubicin are combined.</p> \n<p><b>Discussion</b> In a phase 1 clinical study of 32 patients, coadministration of vinflunine (250 mg/m<sup>2</sup> every 3 weeks or 120 mg/m<sup>2</sup> on day 1 and day 8 every 3 weeks) and doxorubicin (40 mg/m<sup>2</sup> every 3 weeks or 25 mg/m<sup>2</sup> on day 1 and day 8 every 3 weeks) was associated with a high rate of neutropenia, with over 70% of patients experiencing grade 4 neutropenia.<sup>1</sup> No pharmacokinetic interaction was observed.<br><br>Vinflunine product labeling states that although no pharmacokinetic interaction is present when these agents are combined, their concomitant use is associated with a particularly high risk of hematologic toxicities.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zaman K, Durando X, Baurain JF, et al. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer. <i>Breast Cancer Res Treat</i>. 2011;127(3):689-696. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21442199\">[PubMed 21442199]</a></p>\n<p>2. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10676":"<p><b>Title</b> Vinflunine / DOXOrubicin (Liposomal)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DOXOrubicin (Liposomal) may enhance the adverse/toxic effect of Vinflunine. Specifically, the risk for hematologic toxicities may be increased. DOXOrubicin (Liposomal) may increase the serum concentration of Vinflunine. Vinflunine may decrease the serum concentration of DOXOrubicin (Liposomal). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased vinflunine toxicities (eg, neutropenia, neuropathy) if combined with liposomal doxorubicin. Additionally, monitor for decreased doxorubicin effects.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in vinflunine product labeling, coadministration of vinflunine and liposomal doxorubicin resulted in a 15% to 30% increase in vinflunine exposure and a 2- to 3-fold decrease in doxorubicin AUC.<sup>1</sup> The AUC of doxorubicinol (the active metabolite of doxorubicin) was unchanged.<sup>1</sup> In a phase 1 clinical study of 32 patients, coadministration of vinflunine (250 mg/m<sup>2</sup> every 3 weeks or 120 mg/m<sup>2</sup> on day 1 and day 8 every 3 weeks) and conventional doxorubicin (40 mg/m<sup>2</sup> every 3 weeks or 25 mg/m<sup>2</sup> on day 1 and day 8 every 3 weeks) was associated with a high rate of neutropenia, with over 70% of patients experiencing grade 4 neutropenia.<sup>2</sup><br><br>Due to the observed pharmacokinetic alterations with this combination, vinflunine product labeling states that the combination of vinflunine and liposomal doxorubicin should be undertaken with caution.<sup>1</sup><br><br>The mechanism by which a pharmacokinetic interaction may occur between these agents has not been fully investigated, but an in vitro study described in vinflunine product labeling suggests that vinflunine may adhere to the liposomes and modify the serum distribution of both compounds.<sup>1</sup> The increased neutropenia with this combination is likely the result of additive hematologic toxicities because each agent is capable of causing significant neutropenia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p>2. Zaman K, Durando X, Baurain JF, et al. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer. <i>Breast Cancer Res Treat</i>. 2011;127(3):689-696. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21442199\">[PubMed 21442199]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10677":"<p><b>Title</b> Vinflunine / PAZOPanib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PAZOPanib may enhance the adverse/toxic effect of Vinflunine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased neutropenia and liver dysfunction if these agents are combined.</p> \n<p><b>Discussion</b> A phase 1 clinical trial was initiated to evaluate the coadministration of vinflunine (280 to 320 mg/m<sup>2</sup> every 3 weeks) and various doses of pazopanib (200 mg, 400 mg, 600 mg, and 800 mg daily).<sup>1</sup> After treatment of only 5 patients at the pazopanib starting dose of 200 mg daily, the study was terminated early because of safety concerns.<sup>1</sup> One patient developed prolonged febrile neutropenia and another patient developed grade 3 hepatobiliary disorder.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. <i>Anticancer Drugs</i>. 2013;24(4):422-425. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23407060\">[PubMed 23407060]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10678":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Vinflunine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Vinflunine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of vinflunine and QTc-prolonging agents.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Vinflunine product labeling states that because a few cases of vinflunine-associated QTc prolongation have been reported, vinflunine should not be combined with other agents known to prolong the QTc interval.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10679":"<p><b>Title</b> QTc-Prolonging Agents (Moderate Risk) / Vinflunine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Vinflunine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of vinflunine and QTc-prolonging agents.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Moderate Risk) Interacting Members</b> Azithromycin (Systemic), Bedaquiline, Benperidol, Ceritinib, Chloroquine, ChlorproMAZINE, Ciprofloxacin (Systemic), Clarithromycin, Clofazimine, CloZAPine, Crizotinib, Delamanid, Dolasetron, Droperidol, Efavirenz, Erythromycin (Systemic), Escitalopram, Flecainide, Gadobenate Dimeglumine, Gemifloxacin, Goserelin, Granisetron, Haloperidol, Inotuzumab Ozogamicin, Lenvatinib, Leuprolide, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lofexidine, Mequitazine, Methadone, Midostaurin, Moxifloxacin (Systemic), Ofloxacin (Systemic), OLANZapine, Ondansetron, Osimertinib, Panobinostat, PAZOPanib, Pentamidine (Systemic), Pilsicainide, Piperaquine, Primaquine, Probucol, Propafenone, RisperiDONE, Roxithromycin, Saquinavir, Sodium Stibogluconate, Telavancin, Telithromycin, Terlipressin</p>\n</div> \n<p><b>Discussion</b> Vinflunine product labeling states that because a few cases of vinflunine-associated QTc prolongation have been reported, vinflunine should not be combined with other agents known to prolong the QTc interval.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10680":"<p><b>Title</b> Vinflunine / Opioid Analgesics</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Opioid Analgesics may enhance the constipating effect of Vinflunine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required beyond the routine management of constipation that accompanies vinflunine or opioid analgesic use.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> Vinflunine product labeling states that the concomitant use of opioids and vinflunine may increase the risk of constipation.<sup>1</sup> Both agents are associated with constipation and their combined use may have additive effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Javlor (vinflunine) [summary of product characteristics]. St Leonards, New South Wales, Australia: Pierre Fabre Australia Pty Limited; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10681":"<p><b>Title</b> Pilsicainide / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Pilsicainide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased pilsicainide toxicities (eg, QT prolongation, QRS widening, AV block, dizziness) if combined with cimetidine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 9 healthy volunteers, cimetidine (800 mg single dose) increased the pilsicainide (50 mg single dose) AUC 33%, prolonged the elimination half-life 24%, and reduced the renal clearance 28%.<sup>1</sup> <br><br>The mechanism of this interaction has not been fully investigated, but cimetidine-mediated inhibition of the active renal excretion of pilsicainide likely plays a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. <i>Clin Pharmacol Ther</i>. 2000;67(3):222-228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10741624\">[PubMed 10741624]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10683":"<p><b>Title</b> Pilsicainide / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Pilsicainide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Prescribing information states that rifampin may increase CYP450-mediated metabolism of pilsicainide and thus reduce pilsicainide blood concentrations.<sup>1</sup> However, evidence suggests that pilsicainide is mainly eliminated via active renal secretion and CYP450 enzymes are not involved in pilsicainide metabolism.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunrythm (pilsicainide) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200705941. Accessed September 2014.</p>\n<p>2. Tsuruoka S, Ioka T, Wakaumi M, Sakamoto K, Ookami H, Fujimura A. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. <i>Clin Pharmacol Ther</i>. 2006;79(4):389-396. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16580907\">[PubMed 16580907]</a></p>\n<p>3. Plosker GL. Pilsicainide. <i>Drugs</i>. 2010;70(4):455-467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20205487\">[PubMed 20205487]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10690":"<p><b>Title</b> Antiretroviral Agents / Orlistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of Antiretroviral Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased concentrations and effects of antiretroviral agents (eg, elevated HIV viral load, decreased CD4 count) when combined with orlistat. If there is a confirmed increase in HIV viral load, orlistat should be discontinued.</p>\n<div>\n <p><b>Antiretroviral Agents Interacting Members</b> Abacavir, Adefovir, Atazanavir, Bictegravir, Clevudine, Cobicistat, Darunavir, Delavirdine, Didanosine, Dolutegravir, Efavirenz, Elvitegravir, Emtricitabine, Enfuvirtide, Entecavir, Etravirine, Fosamprenavir, Indinavir, LamiVUDine, Lopinavir, Maraviroc, Nelfinavir, Nevirapine, Raltegravir, Rilpivirine, Ritonavir, Saquinavir, Stavudine, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, Tipranavir, Zidovudine</p>\n</div> \n<p><b>Discussion</b> One case report describes an 34-year-old HIV-infected man who had an HIV viral load of less than 50 copies/mL for over a year while taking tenofovir disoproxil fumarate/emtricitabine/efavirenz.<sup>1</sup> Three months after initiation of orlistat (60 mg three times daily), his HIV viral load rose to 722 copies/mL. No resistance mutations were detected and he reported strict adherence to his regimen. After discontinuation of orlistat, his viral load returned to less than 50 copies/mL and remained stable.<sup>1</sup> Another report describes an HIV-infected woman who had an undetectable HIV viral load for several years while taking atazanavir/ritonavir and tenofovir disoproxil fumarate/emtricitabine.<sup>2</sup> One month after initiation of orlistat (60 mg three times daily) her HIV viral load had increased to 440 copies/mL and no resistance mutations were detected. Two months after discontinuation of orlistat, her HIV viral load was again undetectable.<sup>2</sup> Her atazanavir trough concentrations were found to be only 50 ng/mL just prior to orlistat discontinuation and rose to 195 ng/mL 2 months later.<sup>2</sup><br><br>Orlistat prescribing information states that loss of virological control has been reported in HIV-infected patients taking orlistat concomitantly with various antiretroviral drugs (eg, atazanavir, ritonavir, tenofovir disoproxil fumarate, emtricitabine, lopinavir/ritonavir, and emtricitabine/efavirenz/tenofovir disoproxil fumarate).<sup>3</sup> HIV viral load should be frequently monitored in patients who take orlistat while being treated for HIV infection. If there is a confirmed increase in HIV viral load, orlistat should be discontinued.<sup>3</sup><br><br>The mechanism of this interaction has not been fully investigated, but is likely due to inhibition of the absorption of antiretroviral drugs by orlistat. The extent to which orlistat affects each individual antiretroviral agent is unknown, but highly lipophilic drugs (eg, atazanavir, efavirenz) may be more affected than less lipophilic agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kent SJ. Loss of control of HIV viremia associated with the fat malabsorption drug orlistat. <i>AIDS Res Hum Retroviruses</i>. 2012;28(9):961-962. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22280308\">[PubMed 22280308]</a></p>\n<p>2. Gervasoni C, Cattaneo D, Di Cristo V, et al. Orlistat: weight lost at cost of HIV rebound. <i>J Antimicrob Chemother</i>. 2016;71(6):1739-1741. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26945709\">[PubMed 26945709]</a></p>\n<p>3. Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10691":"<p><b>Title</b> BCRP/ABCG2 Substrates / Osimertinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Osimertinib may increase the serum concentration of BCRP/ABCG2 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased concentrations and effects of BCRP substrates if combined with osimertinib.</p>\n<div>\n <p><b>BCRP/ABCG2 Substrates Interacting Members</b> Glecaprevir and Pibrentasvir, PAZOPanib, Rosuvastatin, SulfaSALAzine, Topotecan</p>\n</div> \n<p><b>Discussion</b> In a clinical study described in the osimertinib prescribing information, coadministration of osimertinib and the BCRP substrate rosuvastatin increased the rosuvastatin AUC and maximum serum concentration 35% and 72%, respectively.<sup>1</sup><br><br>Osimertinib prescribing information states that concomitant use of osimertinib and a BCRP substrate may lead to increased exposure of the BCRP substrate.<sup>1</sup> Monitor for exposure-related toxicities of the BCRP substrate if combined.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tagrisso (osimertinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10692":"<p><b>Title</b> Tiludronate / Indomethacin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Indomethacin may increase the serum concentration of Tiludronate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate doses of tiludronate at least two hours before or two hours after indomethacin.</p> \n<p><b>Discussion</b> Per prescribing information for tiludronate, bioavailability of tiludronate is increased by 2- to 4-fold by concomitant indomethacin.<sup>1</sup> Separating tiludronate at least 2 hours before or 2 hours after administration of indomethacin is recommended.<br><br>The mechanism of this interaction is unknown. Coadministration of diclofenac is not associated with increases in tiludronate bioavailability.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Skelid (tiludronate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; April 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10693":"<p><b>Title</b> Tiludronate / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aspirin may decrease the serum concentration of Tiludronate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased effects of tiludronate if chronic aspirin therapy is initiated. Taking aspirin several hours (more than 2 hours) after the dose of tiludronate may help minimize the risk of interaction.</p> \n<p><b>Discussion</b> According to tiludronate prescribing information, administration of aspirin 2 hours after tiludronate may be associated with a reduction in tiludronate bioavailability of up to 50%.<sup>1</sup><br><br>The specific mechanism for this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Skelid (tiludronate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; April 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10694":"<p><b>Title</b> Fenoterol / Inhalational Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Inhalational Anesthetics may enhance the arrhythmogenic effect of Fenoterol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving fenoterol for increased sensitivity to arrhythmias during treatment with inhalational anesthetics.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Fenoterol product labeling states that there is an elevated risk of arrhythmia during concomitant treatment with inhalational anesthetics.<sup>1</sup> No specific data are available, although some data support an elevated risk of arrhythmia when inhalational anesthetics are combined with some other sympathomimetic drugs (eg, ephedrine, epinephrine).<sup>2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fenoterol Hydrobromide [KR prescribing information]. Http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200900974. Accessed February 1, 2016.</p>\n<p>2. Johnston RR, Eger EI II, Wilson C. A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man. <i>Anesth Analg</i>. 1976;55(5):709-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=987729\">[PubMed 987729]</a></p>\n<p>3. Navarro R, Weiskopf RB, Moore MA, et al. Humans anesthetized with sevoflurane or isoflurane have similar arrhythmic response to epinephrine. <i>Anesthesiology</i>. 1994;80(3):545-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7511357\">[PubMed 7511357]</a></p>\n<p>4. Moore MA, Weiskopf RB, Eger EI 2nd, Wilson C, Lu G. Arrhythmogenic doses of epinephrine are similar during desflurane or isoflurane anesthesia in humans. <i>Anesthesiology</i>. 1993;79(5):943-947. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7694528\">[PubMed 7694528]</a></p>\n<p>5. Hahm TS, Lee JJ, Yang MK, Kim JA. Risk factors for an intraoperative arrhythmia during esophagectomy. <i>Yonsei Med J</i>. 2007;48(3):474-479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17594156\">[PubMed 17594156]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10695":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Indapamide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Some of these combinations are specifically contraindicated or advised against in some non-U.S. labeling for indapamide-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Indapamide may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of arrhythmia or QTc prolongation with use of indapamide and drugs considered to have a high risk of causing QTc prolongation or Torsade de Pointes (TdP). Some non-U.S. labeling for indapamide-containing products specifically contraindicates use with class I or class III antiarrhythmics, and several characterize combinations with QTc prolonging products as inadvisable.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Several published reports describe patients who experienced prolongation of the QT interval that was at least partially attributed to use of indapamide and its associated electrolyte disturbances.<sup>1,2,3,4,5</sup> The US prescribing information for indapamide does not contain any specific warning regarding QT prolongation or TdP,<sup>6</sup> but some international labels do contraindicate, advise against, or recommend caution when combining indapamide with QTc-prolonging medications.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Quek DK, H'ng PK. Torsade de pointes and sudden death associated with diabetic autonomic diarrhoea--a case report. <i>Singapore Med J</i>. 1993;34(3):266-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8266190\">[PubMed 8266190]</a></p>\n<p>2. Wang CP, Guo GB. Indapamide induced syncope in a patient with long QT syndrome. <i>Pacing Clin Electrophysiol</i>. 2002;25(9):1397-1309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12380780\">[PubMed 12380780]</a></p>\n<p>3. Letsas KP, Alexanian IP, Pappas LK, et al. QT interval prolongation and torsade de pointes associated with indapamide. <i>Int J Cardiol</i>. 2006;112(3):373-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16260053\">[PubMed 16260053]</a></p>\n<p>4. Mok NS, Tong CK, Yuen HC. Concomitant-acquired Long QT and Brugada syndromes associated with indapamide-induced hypokalemia and hyponatremia. <i>Pacing Clin Electrophysiol</i>. 2008;31(6):772-775. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18507554\">[PubMed 18507554]</a></p>\n<p>5. Yong TY, Huang JE, Lau SY, Li JY. Severe hyponatremia and other electrolyte disturbances associated with indapamide. <i>Curr Drug Saf</i>. 2011;6(3):134-137. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22122387\">[PubMed 22122387]</a></p>\n<p>6. Lozol (indapamide) [prescribing information]. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; July 2005.</p>\n<p>7. Triplixam (amlodipine, indapamide, perindopril) [summary of product characteristics]. Arklow, Co. Wicklow, Ireland: Servier (Ireland) Industries Ltd.; May 2016.</p>\n<p>8. Coversyl Plus (perindopril/indapamide) [product monograph]. Laval, Quebec, Canada: Servier Canada Inc.; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10696":"<p><b>Title</b> TiaGABine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Approximately 2-fold higher tiagabine doses and a more rapid dose titration will likely be required in patients concomitantly taking an enzyme-inducing antiepileptic drug. Use with other strong CYP3A4 inducers will likely result in a similar interaction. In patients not taking strong CYP3A4 inducers or who have discontinued CYP3A4-inducing agents, a more gradual dose titration and/or an approximately 50% lower dose may be needed.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Population pharmacokinetic analyses described in the tiagabine prescribing information indicate that tiagabine clearance is 60% greater when combined with enzyme-inducing antiepileptic drugs (ie, carbamazepine, phenytoin, phenobarbital, primidone), potentially resulting in decreased tiagabine concentrations.<sup>1</sup> In a study of 24 patients stabilized on 1 to 3 enzyme-inducing antiepileptic drugs and initiated on tiagabine (24 mg, 40 mg, 56 mg, or 80 mg daily), dose-adjusted half-lives of tiagabine were approximately 40% shorter than those of 30 historical control subjects not coadministered enzyme-inducing antiepileptic drugs.<sup>2</sup> <br><br>Strong CYP3A4 inducers are likely to increase the metabolism of tiagabine, a CYP3A4 substrate, resulting in greater clearance and lower serum concentrations of tiagabine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gabitril (tiagabine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; August 2016.</p>\n<p>2. So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. <i>Epilepsy Res</i>. 1995;22(3):221-226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8991789\">[PubMed 8991789]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10697":"<p><b>Title</b> BuPROPion / CYP2B6 Inhibitors (Weak)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2B6 Inhibitors (Weak) may increase the serum concentration of BuPROPion. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased bupropion effects/toxicities if combined with weak CYP2B6 inhibitors. Decreased doses may be required. The maximum recommended dose of the naltrexone/bupropion (8 mg/90 mg) product is one tablet twice daily in patients receiving CYP2B6 inhibitors. Because the Forfivo XL product is only available at the 450 mg dose (the maximum bupropion dose), use of CYP2B6 inhibitors and the Forfivo XL product should be avoided.</p>\n<div>\n <p><b>CYP2B6 Inhibitors (Weak) Interacting Members</b> Clopidogrel, Rolapitant, Ticlopidine<br><b>Exception</b> Prasugrel</p>\n</div> \n<p><b>Discussion</b> In clinical studies, the single-dose maximum concentration (Cmax) and AUC of bupropion were increased by 40% and 60%, respectively, during coadministration of clopidogrel (75 mg daily) and by 38% and 85%, respectively, during coadministration with ticlopidine (250 mg twice daily).<sup>1,2,3,4,5, 6</sup> The Cmax and AUC of the metabolite hydroxybupropion were reduced by 50% and 52%, respectively, with clopidogrel and by 78% and 84%, respectively, with ticlopidine. <br><br>In contrast, coadministration of bupropion with the weakest CYP2B6 inhibitor prasugrel only increased the bupropion AUC 18%, a change considered to be clinically insignificant.<sup>1,2,3,4,5,7</sup><br><br>The suspected primary mechanism of these interactions is inhibition of CYP2B6-mediated bupropion metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aplenzin (bupropion hydrobromide) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2014.</p>\n<p>2. Contrave (naltrexone/bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc; September 2014.</p>\n<p>3. Forfivo XL (bupropion hydrochloride) [prescribing information]. Austin, TX: Edgemont Pharmaceuticals LLC; August 2016.</p>\n<p>4. Wellbutrin XL (bupropion hydrochloride) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2014.</p>\n<p>5. Zyban (bupropion hydrochloride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2016.</p>\n<p>6. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. <i>Clin Pharmacol Ther</i>. 2005;77(6):553-559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15961986\">[PubMed 15961986]</a></p>\n<p>7. Farid NA, Payne CD, Ernest CS 2nd, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. <i>J Clin Pharmacol</i>. 2008;48(1):53-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094219\">[PubMed 18094219]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10698":"<p><b>Title</b> Zolpidem / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Zolpidem. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider avoiding the combination of ciprofloxacin and zolpidem if possible. If combined, monitor for signs of zolpidem toxicity (eg, somnolence, dizziness, lethargy).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 18 healthy volunteers, ciprofloxacin (500 mg daily) increased the zolpidem (single 5 mg dose) AUC and maximum serum concentration by 46% and 6%, respectively.<sup>1</sup><br><br>Zolpidem prescribing information states that ciprofloxacin is likely to inhibit several metabolic pathways responsible for zolpidem metabolism, potentially leading to an increase in zolpidem exposure.<sup>2</sup> Ciprofloxacin prescribing information states that concomitant use of ciprofloxacin and zolpidem is not recommended.<sup>3</sup><br><br>The mechanism of this interaction is likely due to ciprofloxacin-mediated inhibition of CYP3A4 and CYP1A2, enzymes involved in zolpidem metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. <i>Eur J Drug Metab Pharmacokinet</i>. 2011;35(3-4):83-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21302033\">[PubMed 21302033]</a></p>\n<p>2. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2016.</p>\n<p>3. Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10699":"<p><b>Title</b> Zolpidem / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Zolpidem. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, clarithromycin (500 mg x 4 doses given over 32 hours) increased the zolpidem (5 mg single dose) AUC and maximum serum concentration 4% and 11%, respectively, but these changes did not reach statistical significance.<sup>1</sup><br><br>Zolpidem prescribing information states that the combined use of zolpidem and strong CYP3A4 inhibitors (ie, clarithromycin) may increase the effects of zolpidem.<sup>2</sup> <br><br>The mechanism of this potential interaction is likely due to clarithromycin-mediated inhibition of CYP3A4, an enzyme partially responsible for zolpidem metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodyamic effects of trazodone but not of zolpidem. <i>Clin Pharmacol Ther</i>. 2009;85(6):644-650. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19242403\">[PubMed 19242403]</a></p>\n<p>2. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}